ReviewReported positiveLimited evidenceTier 4 · clinical
Drugs · Jun 2026 · regulatory approval summary
Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.
Studied with: nab-paclitaxel.
Key findings
- Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
- Relacorilant received first approval in the USA on 25 March 2026.
- Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
- Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
- The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positiveModerate evidenceTier 4 · clinical
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · Sep 2025 · narrative review
ovarian cancerfallopian tube cancerperitoneal cancerepithelial ovarian cancersovarian germ cell malignanciesovarian stromal malignancies
This is a narrative review updating FIGO staging and summarizing current knowledge on ovarian, fallopian tube, and peritoneal cancers. It describes the 2014 FIGO staging revisions (including subdivisions of Stage IC and IIIC/IIIA) and summarizes genetics, surgical management, chemotherapy, targeted therapies, and aspects of germ cell and stromal ovarian malignancies. The review notes that high-grade serous carcinoma is the most common histology and that no feasible screening strategies currently exist.
Key findings
- FIGO's 2014 staging revision groups ovarian, fallopian tube, and peritoneal cancers in the same system and subdivides Stage IC into IC1 (surgical spill), IC2 (preoperative capsule rupture or tumor on surface), and IC3 (malignant cells in ascites or peritoneal washings).
- Stage IIIC was revised to include a category for spread to retroperitoneal lymph nodes without intraperitoneal dissemination, subdivided into IIIA1(i) (metastasis ≤10 mm) and IIIA1(ii) (metastasis >10 mm); Stage IIIA2 is now defined as microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph nodes.
- Most of these malignancies are high-grade serous carcinomas (HGSCs).
- There are currently no feasible screening strategies for ovarian cancer.
- Diagnosis, treatment, surveillance, and survival have improved due to advances in radiology, pathology, genomics, and molecular biology, and individualized care emphasizes precision surgery to limit morbidity.
- Germline genetic analysis and identification of somatic mutations in tumor tissue provide data informing the use of targeted agents and immunotherapy; the review also covers chemotherapy and management of germ cell and stromal ovarian malignancies.
Limitations: Narrative review with no original patient-level data presented; Abstract does not report review methods, search strategy, or criteria for evidence selection (not identified as a systematic review or meta-analysis); No new primary quantitative data or pooled estimates provided in this abstract.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381
Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial
Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.
Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more
Studied with: nab-paclitaxel.
Key findings
- Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
- An interim overall survival analysis also favored the combination.
- Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewMixed resultsModerate evidenceTier 4 · clinical
Journal of the National Comprehensive Cancer Network : JNCCN · Oct 2024 · Practice guideline / guideline insights
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
These NCCN Guidelines Insights summarize multidisciplinary diagnostic workup, staging, and treatment recommendations for ovarian, fallopian tube, and primary peritoneal cancers. The report specifically describes how the evolving use of PARP inhibitors as maintenance and single-agent regimens informed the panel's recommendations.
Key findings
- NCCN Guidelines provide multidisciplinary diagnostic workup, staging, and treatment recommendations for ovarian, fallopian tube, and primary peritoneal cancers.
- The Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens informed panel recommendations in the guidelines.
Limitations: Abstract is a guideline summary and does not present original trial data or numerical results.; No specific recommendations, dosing, comparative efficacy, or level-of-evidence details are provided in the abstract.; Limited methodological detail in abstract about how evidence was reviewed or how recommendations were updated..
Guideline update addressing clinical management of ovarian/fallopian tube/primary peritoneal cancers with attention to PARP inhibitor use.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 100
Journal of gynecologic oncology · Sep 2024 · Phase III randomized controlled trial, randomized 1:1
Bevacizumabepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancer This randomized phase III trial assigned 100 Chinese patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer after surgery to carboplatin/paclitaxel with either bevacizumab or placebo. Median progression-free survival was 22.6 months with bevacizumab plus chemotherapy versus 12.3 months with placebo plus chemotherapy (stratified HR 0.30, 95% CI 0.17–0.53). Treatment-related grade 3/4 adverse events were more frequent in the bevacizumab arm.
Reported effects: median PFS 22.6 mo · stratified hazard ratio for PFS 0.3 [0.17–0.53] · +1 more
Studied with: carboplatin, paclitaxel.
Key findings
- Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP.
- Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53).
- Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP.
Limitations: Relatively small randomized sample (100 patients).; Primary endpoint was investigator-assessed PFS (no central review stated).; Overall survival and longer-term outcomes not reported in the abstract.; Single-country (China) population may limit generalizability to other populations.; Adverse-event denominators reported in the abstract are inconsistent with the randomized-arm counts, which complicates interpretation of safety rates..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialInconclusiveModerate evidenceTier 4 · clinical
Journal of gynecologic oncology · Jul 2024 · phase 3, randomized, 2-arm, open-label, global multicenter study protocol
Relacorilantadvanced platinum-resistant ovarian cancerrecurrent platinum-resistant high-grade serous epithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This paper describes the ROSELLA phase 3 trial, which is testing relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in women with recurrent platinum-resistant ovarian and related cancers. The study is designed to see whether adding relacorilant improves progression-free survival and other outcomes, and it will also assess safety and patient-reported outcomes. The abstract does not report trial results, only the study plan.
Studied with: nab-paclitaxel.
Key findings
- ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter study.
- Participants are assigned 1:1 to relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy.
- Primary endpoint is progression-free survival assessed by blinded independent central review.
- Secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate at 24 weeks, and CA-125 response.
- The abstract reports no efficacy or safety results because it is a trial protocol.
Limitations: Protocol only; no outcomes or results are reported in the abstract.; No sample size is provided in the abstract.; No quantitative effect estimates are available.; Open-label design may introduce bias in some endpoints..
This is a phase 3 protocol in platinum-resistant ovarian cancer evaluating an anticancer combination.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text